| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RUNX1 |
| Uniprot No | Q01196 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 210-311aa |
| 氨基酸序列 | RVSPHHPAPTPNPRASLNHSTAFNPQPQSQMQDTRQIQPSPPWSYDQSYQ YLGSIASPSVHPATPISPGRASGMTTLSAELSSRLSTAPDLTAFSDPRQF P |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于RUNX1重组蛋白的经典文献摘要概括：
1. **文献名称**: Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFβ
**作者**: Tahirov T.H. et al.
**摘要**: 通过X射线晶体学解析RUNX1(AML1)Runt结构域与DNA及CBFβ蛋白的复合物结构，揭示了RUNX1通过β折叠片结合DNA双螺旋，而CBFβ通过稳定Runt结构域构象增强其DNA结合能力。
2. **文献名称**: The RUNX1/RUNX1T1 network: translating insights into therapeutic approaches
**作者**: Backvall H. et al.
**摘要**: 系统综述RUNX1重组蛋白(如白血病相关的RUNX1-ETO)在转录调控和信号转导中的分子机制，强调其与染色质修饰复合物(如Sin3A/HDAC)的相互作用对白血病的调控作用。
3. **文献名称**: Cloning and characterization of the human AML1 gene
**作者**: Okuda T. et al.
**摘要**: 首次报道人源RUNX1(AML1)基因的克隆及重组蛋白表达，证实其在造血干细胞分化和T细胞受体增强子激活中的关键功能，为后续白血病相关融合蛋白研究奠定基础。
4. **文献名称**: The t(8;21) translocation in leukemia modifies RUNX1 DNA-binding activity via recruitment of corepressors
**作者**: Yergeau D.A. et al.
**摘要**: 通过重组RUNX1-ETO融合蛋白实验，揭示其通过异常招募核受体共抑制复合物(N-CoR/SMRT)抑制靶基因表达，导致造血分化阻滞的分子机制。
RUNX1 (Runt-related transcription factor 1), also known as AML1 or CBFA2. is a critical transcriptional regulator involved in hematopoiesis, cell differentiation, and embryonic development. As a member of the RUNX family, it contains a conserved Runt homology domain (RHD) responsible for DNA binding and heterodimerization with its co-factor CBFβ. The C-terminal region includes transcriptional activation/repression domains that mediate interactions with chromatin modifiers and other transcription factors. RUNX1 plays a pivotal role in definitive hematopoiesis, directing the formation of hematopoietic stem cells (HSCs) and regulating lineage-specific genes in myeloid and lymphoid cells.
Recombinant RUNX1 protein, produced via bacterial or eukaryotic expression systems, is widely used to study its biochemical properties, DNA-binding mechanisms, and regulatory networks. Its purified form enables in vitro assays like electrophoretic mobility shift assays (EMSAs), chromatin immunoprecipitation (ChIP), and structural studies (e.g., X-ray crystallography). Researchers also employ recombinant RUNX1 to investigate its interactions with co-factors (e.g., CBFβ, ETS family proteins) and epigenetic modifiers (e.g., p300. SIN3A).
Dysregulation of RUNX1 is strongly associated with hematologic malignancies. Chromosomal translocations (e.g., RUNX1-ETO in AML) or mutations impair its function, leading to differentiation arrest and leukemogenesis. Recombinant mutant RUNX1 proteins are tools for modeling these pathologies, screening targeted therapies, and deciphering resistance mechanisms. Despite progress, challenges remain in recapitulating post-translational modifications (e.g., phosphorylation, acetylation) critical for its activity, underscoring the need for advanced expression systems to produce functionally mature recombinant RUNX1 for translational research.
×
